1 |
Godring, S. R. and Gravallese, E. M. : Mechanisms of bone loss in inflammatory arthritis: Diagnosis and therapeutic implications. Arthritis Res. 2, 33 (2000).
DOI
|
2 |
Rodan, G. A. and Martin, T. J. : Role of osteoblasts in hormonal control of bone resorption-a hypothesis. Calcif. Tissue Int. 33, 349 (1981).
DOI
|
3 |
Suda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M. T. and Martin, T. J. : Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20, 345 (1999).
DOI
|
4 |
Takahasi, N., Akatsu, T., Udagawa, N., Sasaki, T., Yamaguchi, A., Moseley, J. M., Martin, T. J. and Suda, T. : Osteoblastic cells are involved in osteoclast formation. Endocrinology 123, 2600 (1988).
DOI
|
5 |
Takayanagi, H., Ogasawara, K., Hida, S., Chiba, T., Murata, S., Sato, K., Takaoka, A., Yokochi, T., Oda, H., Tanaka, K., Nakamur, K. and Taniguchi, T. : T-cell-mediated regulation of osteoclastogenesis by signaling cross-talk between RANKL and IFN- . Nature 408, 600 (2000).
DOI
|
6 |
Phan, T. C. A., Xu, J. and Zheng, M. H. : Interaction between osteoblast and osteoclast : impact in bone disease. Histol. Histo. Phatol. 19, 1325 (2004).
|
7 |
Asagiri, M. and Takayanagi, H. : The molecular understanding of osteoclast differentiation. Bone 40, 251 (2007).
DOI
|
8 |
Kong, Y. Y., Feige, U., Sarosi, I., Bolon, B., Tafuri, A., Morony, S., Capparelli, C., Li, J., Elliott, R., McCabe, S., Wong, T., Campagnuolo, G., Moran, E., Bogoch, E. R., Van, G., Nguyen, L. T., Ohashi, P. S., Lacey, D. L., Fish, E., Boyle, W. J. and Penningeral, J. M. : Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402, 304 (1999).
DOI
|
9 |
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelly, M., Chang, M. S., Luthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., Shimamoto, G., DeRose, M., Elliott, R., Colombero, A., Tan, H. L., Trail, G., Sullivan, J., Davy, E., Bucay, N., Renshaw-Gegg, L., Hughes, T. M., Hill, D., Pattison, W., Campbell, P. and Boyle, W. J. : Osteoprotegerin : A novel secreted protein involved in the regulation of bone density. Cell 89, 309 (1997).
DOI
|
10 |
Yasuda, H., Shima, N., Nakagawa, N., Mochizuki, S. I., Yano, K., Fujise, N., Sato, Y., Goto, M., Ymaguchi, K., Kuriyama, M., Kanno, T., Murakami, A., Tsuda, E., Morinaga, T. and Higashio, K. : Identity of osteoclastogenesis inhibitory factor (ocif) and osteoprotegerin (opg): A mechanism by which opg/ocif inhibits osteoclastogenesis in vitro. Endocrinology 139, 1329 (1998).
DOI
|
11 |
Buckley, K. A., Hipskind, R. A., Gartland, A., Bowler, W. B. and Gallagher, J. A. : Adenosine triphosphate stimulates human osteoclast activity via upregulation of osteoblast-expressed receptor activator of nuclear factor-kappa B ligand. Bone 31, 582 (2002).
DOI
|
12 |
Lazarowski, E. R., Boucher, R. C. and Harden, T. K. : Mechanisms of release of nucleotides and integration of their action as P2X- and P2Y-receptor activating molecules. Mol. Pharmacol. 64, 785 (2003).
DOI
|
13 |
Ralevic, V. and Brunstock, G. : Receptors for purines and pyrimidines. Pharmacol. Rev. 50, 413 (1998).
|
14 |
Jorgensen, N. R., Solgaard, M. and Schwarz, P. : Role of P2 purinergic receptors in bone metabolism and their therapeutic potential. Med. Hypothesis Res. 3, 615 (2006).
|
15 |
Jacobson, K. A., Jarvis, M. F. and Williams, M. : Purines and pyrimidine (P2) receptors as drug targets. J. Med. Chem. 45, 4057 (2002).
DOI
|
16 |
Von Kugelgen, I. : Pharmacological profiles of cloned mammalin P2Y-receptor subtypes. Pharmacol. Ther. 110, 415 (2006).
DOI
|
17 |
Communi, D., Janssens, R., Suraex-Huerta, N., Robaye, B. and Boeynaems, J. M. : Advances in signaling by extracellular nucleotides. the role and transduction mechanisms of P2Y receptor. Cell Signal. 12, 351 (2000).
DOI
|
18 |
Burnstock, G. and Knight, G. E. : Cellular distribution and functions of P2 receptor subtypes in different system. Int. Rev. Cytol. 240, 31 (2004).
DOI
|
19 |
Steinberg, T. H. and Hiken, J. F. : P2 receptors in macrophage fusion and osteoclast formation. Purinergic Signaling 3, 53 (2007).
DOI
|
20 |
Orriss, I. R., Wang, N., Burnstock, G., Arnett, T. R., Gartland, A., Robaye, B. and Noeynaems, J. : The receptor stimulates bone resorption by osteoclasts. Endocrinology 152, 3706 (2011).
DOI
|
21 |
Korcok, J., Raimundo, L. N., Du, X., Sims, S. M. and Dixon, S. J. : P2Y6 nucleotide receptors activate and increase survival of osteocalsts. J. Biol. .Chem. 280, 16909 (2005).
DOI
|
22 |
Lee, J. H., Jin, H., Shim, H. E., Kim, H. N., Ha, H. and Lee, Z. H. : Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the NF- signal. Mol. Pharmacol. 77, 17 (2010).
DOI
|
23 |
Zhang, Z., Wang, Z., Ren, H., Yue, M., Huang, K., Gu, H., Liu, M., Du, B. and Qian, M. : P2Y6 agonist uridine 5'-diphosphate promotes host defense against bacterial infection via monocyte chemoattractant protein-1-mediated monocytes/macrophages recruitment. J. Immunol. 186, 5376 (2011).
DOI
|
24 |
Orriss, I. R., Wang, N., Burnstock, G., Arnett, T. R., Gartland, A., Robaye, B. and Boeynaems, J. M. : The P2Y(6) receptor stimulates bone resorption by osteoclasts. Endocrinology 152, 3706 (2011).
DOI
|
25 |
Murillo, A., Guerrero, C. A., Acosta, O. and Cardozo, C. A. : Bone resorptive activity of osteoclast-like cells generated in vitro by PEG-induced macrophage fusion. Biol. Res. 43, 205 (2010).
|
26 |
Takayanagi, H. : Osteoimmunology: shared mechanisms and crosstalk between the immun and bone systems. Nat. Rev. Immunol. 7, 292 (2007).
DOI
|
27 |
Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H. L., Ellioti, G., Kelly, M. J., Sarosi, I., Wang, L., Xia, X. Z., Elliott, R., Chiu, L., Black, T., Scully, S., Capparelli, C., Morony, S., Shimamoto, G., Bass, M. N. and Boyle, W. J. : Tumor necrosis factor receptor family member rank mediates osteoclast differentiation and actiation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. USA 96, 3540 (1999).
DOI
|
28 |
Kim, K., Kim, J. H., Lee, J., Jin, H. M., Kook, H., Kim, K. K., Lee, S. Y. and Kim, N. : MafB negatively regulates RANKL-mediated osteoclast differentiation. Blood 109, 3253 (2007).
DOI
|
29 |
Takayanagi, H., Kim, S., Koga, T., Nishina, H., Isshiki, M., Yoshida, H., Saiura, A., Isobe, M., Yokochi, T., Inoue, J., Wagner, E. F., Mak, T. W., Kodama, T. and Taniguchi, T. : Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell. 3, 889 (2002).
DOI
|
30 |
Takayanagi, H. : The role of NFAT in osteoclast formation. Ann. NY. Acad. Sci. 1116, 227 (2007).
DOI
|
31 |
Martins, G. and Calame, K. : Regulation and functions of Blimp-1 in T and B lymphocytes. Annu. Rev. Immunol. 26, 133 (2008).
DOI
|
32 |
Nishikawa, K., Nakashima, T., Hayashi, M., Fukunaga, T., Kato, S., Kodama, T., Takahashi, S., Calame, K. and Takayanagi, H. : Blimp1-mediated repression of negative regulators is required for osteoclast differentiation. Proc. Natl. Acad. Sci. USA 107, 3117 (2010).
DOI
|